AE Wealth Management LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,690 shares of the medical equipment provider’s stock, valued at approximately $541,000.
Other hedge funds have also recently modified their holdings of the company. FinTrust Capital Advisors LLC purchased a new position in shares of Lantheus in the 2nd quarter worth about $26,000. Dupont Capital Management Corp purchased a new position in shares of Lantheus in the 2nd quarter worth about $32,000. Focused Wealth Management Inc purchased a new position in shares of Lantheus in the 3rd quarter worth about $63,000. Financial Gravity Asset Management Inc. purchased a new position in shares of Lantheus in the 2nd quarter worth about $2,319,000. Finally, Spire Wealth Management purchased a new position in shares of Lantheus in the 2nd quarter worth about $119,000. Institutional investors own 97.62% of the company’s stock.
Analyst Upgrades and Downgrades
LNTH has been the subject of several recent analyst reports. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, November 4th. Mizuho started coverage on Lantheus in a report on Wednesday, October 12th. They issued a “buy” rating and a $105.00 price objective for the company. SVB Leerink started coverage on Lantheus in a report on Wednesday, November 30th. They issued an “outperform” rating for the company. Finally, Jonestrading started coverage on Lantheus in a report on Thursday, October 6th. They issued a “buy” rating and a $104.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Lantheus currently has an average rating of “Buy” and an average target price of $102.80.
Lantheus Trading Up 3.4 %
Lantheus (NASDAQ:LNTH – Get Rating) last announced its earnings results on Thursday, November 3rd. The medical equipment provider reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.15. The business had revenue of $239.29 million for the quarter, compared to analysts’ expectations of $228.52 million. Lantheus had a return on equity of 37.77% and a net margin of 13.35%. Analysts expect that Lantheus Holdings, Inc. will post 3.52 EPS for the current year.
Insiders Place Their Bets
In other Lantheus news, COO Paul Blanchfield sold 2,432 shares of the firm’s stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $54.79, for a total value of $133,249.28. Following the transaction, the chief operating officer now directly owns 73,968 shares of the company’s stock, valued at $4,052,706.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Paul Blanchfield sold 2,432 shares of the stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $54.79, for a total value of $133,249.28. Following the completion of the sale, the chief operating officer now directly owns 73,968 shares of the company’s stock, valued at approximately $4,052,706.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Andrea Sabens sold 386 shares of Lantheus stock in a transaction that occurred on Monday, October 17th. The shares were sold at an average price of $70.50, for a total transaction of $27,213.00. Following the transaction, the chief accounting officer now directly owns 62,004 shares in the company, valued at approximately $4,371,282. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,718 shares of company stock valued at $1,653,303. Insiders own 1.60% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.